View More Recent Stories
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
Faruqi & Faruqi Reminds Sana Biotechnology Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
-
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
-
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
-
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
H.C. Wainwright Reiterates Buy Rating on Sana Biotechnology (SANA)
-
Citizens JMP Upgrades Sana Biotechnology (SANA) to Market Outperform
-
Sana Biotechnology, Inc. (SANA) Tops Q4 EPS by 1c
-
Jefferies Starts Sana Biotechnology (SANA) at Buy
-
Sana Biotechnology (SANA) PT Raised to $11 at H.C. Wainwright
-
BofA Securities Reiterates Buy Rating on Sana Biotechnology (SANA)
-
TD Cowen Upgrades Sana Biotechnology (SANA) to Buy
-
After-hours movers: Flutter Entertainment, DraftKings, Cal-Maine Foods, and more
-
Sana Biotechnology (SANA) Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
-
Sana Biotechnology (SANA) Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
-
H.C. Wainwright Reiterates Buy Rating on Sana Biotechnology (SANA)
-
H.C. Wainwright Reiterates Buy Rating on Sana Biotechnology (SANA)
-
Sana Biotechnology, Inc. (SANA) Tops Q3 EPS by 1c
-
Sana Biotechnology (SANA) PT Lowered to $8 at H.C. Wainwright
-
JMP Securities Downgrades Sana Biotechnology (SANA) to Market Perform
-
Sana Biotechnology (SANA) Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2
-
Sana Biotechnology (SANA) Announces CFO Resignation
-
Sana Biotechnology (SANA) Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
-
Increasing unusual call option volume: SANA LUNR URBN ROIV BEN BBAI VIPS BJ CPRI IVR GSAT
-
Sana Biotechnology (SANA) PT Raised to $15 at Citi, Opens Positive Catalyst Watch
-
Sana Biotechnology, Inc. (SANA) Misses Q2 EPS by 4c
-
GSK (GSK) and Flagship Pioneering partner to discover novel medicines and vaccines

